Pharming (PHAR) Research & Development (2020 - 2026)

Pharming (PHAR) has 7 years of Research & Development data on file, last reported at -$57.8 million in Q2 2026.

• Quarterly Research & Development fell 28.95% year-over-year to -$57.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$183.7 million (down 23.21% YoY) and the FY2025 annual result came in at $100.4 million, up 20.78% from the prior year.
• Research & Development eased to -$57.8 million in Q2 2026, from -$25.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of -$20.7 in Q3 2024 to a low of -$100.4 million in Q4 2025.
• A 5-year average of -$30.8 million and a median of -$20.9 million in 2023 frame the typical range for Research & Development.
• The widest YoY moves for Research & Development: up 100.0% in 2024, down 191952053.11% in 2024.
• Tracing PHAR's Research & Development over 5 years: stood at -$52.5 million in 2022, then soared by 100.0% to -$57.3 in 2023, then sank by 145108102.44% to -$83.1 million in 2024, then slipped by 20.71% to -$100.4 million in 2025, then jumped by 42.39% to -$57.8 million in 2026.
• The last three Research & Development figures came in at -$57.8 million (Q2 2026), -$25.6 million (Q1 2026), and -$100.4 million (Q4 2025), per Business Quant data.